Testing MK-4208 in adults with chronic myeloid leukemia
Tests MK-4208 for safety and dose levels in adults with chronic myeloid leukemia.
Key facts
- Who runs it
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Where
- Anyang-si, Busan, Daegu, and Uijeongbu-si, South KoreaSee the 4 sitesAlso in 8 other countries, 49 sites
- Trial code
- Registry title
- A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 330 people, planned
- Started
- 26 Mar 2024
- Expected to end
- 31 May 2030
- Type of study
- Interventional, 10 groups
- Treatments tested
- MK-4208
- Record updated
- 15 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic myeloid leukemia (CML) in the chronic phase. Their earlier TKI treatment must have failed, worked poorly, or caused side effects they could not tolerate.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- BCR-ABL1 positive chronic myeloid leukemia in the chronic phase, confirmed by cell tests.
- Earlier treatment
- Must have had at least 1 earlier tyrosine kinase inhibitor (TKI) with treatment failure, a weak response, or intolerance. Earlier asciminib is allowed. No cancer drug treatment in the 7 days before the first dose.
- Biomarker or test result
- BCR-ABL1 positive CML.
Main reasons for not taking part
- Cancer drug treatment (including TKIs, interferon-alfa, antibodies, chemotherapy) or other experimental treatment within 7 days before the first dose
- Side effects from earlier cancer treatment that have not gone down to Grade 2 or the starting level
- Organ function that is not adequate on local lab tests
- ECOG performance status score above 2
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase
- Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
- Prior treatment with asciminib is allowed
- Adequate organ function, as assessed by local laboratory
Who cannot take part
- Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701
- Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in South Korea
Also in 8 other countries, 49 sites
- Hallym University Sacred Heart HospitalAnyang-si, South KoreaContact: Toll Free NumberTaking people
- Dong-A University HospitalBusan, South KoreaContact: Toll Free NumberTaking people
- Keimyung University Dongsan HospitalDaegu, South KoreaContact: Toll Free NumberTaking people
- Uijeorigbu Eulji Medical Center, Eulji UniversityUijeongbu-si, South KoreaContact: Toll Free NumberTaking people
About the trial
What the trial wants to find out
Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.
Read full original descriptionShow less
The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.
The 10 groups in the trial
- Part 1 - MK-4208 160 mg once daily (QD)Treatment being tested
Participants receive MK-4208 160 mg orally QD.
Treatment: MK-4208
- Part 1- MK-4208 320 mg QDTreatment being tested
Participants receive MK-4208 320 mg orally QD.
Treatment: MK-4208
- Part 1- MK-4208 400 mg QDTreatment being tested
Participants receive MK-4208 400 mg orally QD.
Treatment: MK-4208
- Part 1- MK-4208 500 mg QDTreatment being tested
Participants receive MK-4208 500 mg orally QD.
Treatment: MK-4208
- Part 2 - MK-4208 320 mg QDTreatment being tested
Participants receive MK4208 320 mg orally QD.
Treatment: MK-4208
- Part 2 - MK-4208 500 mg QDTreatment being tested
Participants receive MK4208 500 mg orally QD.
Treatment: MK-4208
- Part 2m - MK-4208 320 mg twice per day (BID)Treatment being tested
Participants receive MK4208 320 mg orally BID.
Treatment: MK-4208
- Part 2m - MK-4208 500 mg QDTreatment being tested
Participants receive MK-4208 500 mg orally QD.
Treatment: MK-4208
- Part 2m - MK4208 500 mg BIDTreatment being tested
Participants receive MK4208 500 mg orally BID.
Treatment: MK-4208
- Part 3 - MK-4208 500 mg QDTreatment being tested
Participants receive MK-4208 500 mg QD
Treatment: MK-4208
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
- Plain-language title
- Testing MK-4208 in adults with chronic myeloid leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06163430, who can take part
- Record updated
- 15 October 2026